We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+0.46%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$282M
AUM Growth
-$64M
Cap. Flow
-$55M
Cap. Flow %
-19.54%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$85.9M 30.5%
3,468,495
– –
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$65.8M 23.36%
1,554,744
-1,500,000
-49% -$55M
NSTG
3
DELISTED
NanoString Technologies, Inc.
NSTG
$59.2M 21.02%
3,959,440
– –
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$43.4M 15.41%
2,579,062
– –
TLOG
5
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$27.4M 9.71%
4,644,705
– –

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q2 2014 Portfolio in Review

As of Q2 2014, Clarus Ventures held 5 positions worth $282M, down 19% from $346M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures withdrew a net $55M in Q2 2014, reducing 1 holding. Its largest reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures's biggest Q2 2014 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $55M.
  • Clarus Ventures's ten largest holdings make up 100% of its $282M portfolio in Q2 2014.
  • Clarus Ventures opened 0 new positions and closed 0 in Q2 2014.
  • Clarus Ventures's portfolio value fell 19% quarter-over-quarter to $282M.

Based on Clarus Ventures's 13F filing for Q2 2014, filed 12 Aug 2014.